Literature DB >> 6137948

Thermogenic and antiobesity activity of a novel beta-adrenoceptor agonist (BRL 26830A) in mice and rats.

J R Arch, A T Ainsworth.   

Abstract

The effects of a novel compound, BRL 26830A, on energy balance in normal and obese mice have been investigated. BRL 26830A reduced body weight or weight gain in genetically (ob/ob), goldthioglucose, and cafeteria diet obese mice and genetically obese (fa/fa) Zucker rats. Weight reduction was due to reduced body lipid content. BRL 26830A caused little or no reduction in food intake in these animals but it increased metabolic rate and in genetically obese mice this thermic effect was increased by repeat dosing. BRL 26830A did not reduce body weight gain in the lean counterparts of the genetically obese animals. Its thermic effect was smaller in the lean than the genetically obese mice and it caused an increase in food intake in the lean mice. The thermic effect of BRL 26830A was inhibited by dl- but not d-propranolol. BRL 26830A largely overcame the depression in metabolic rate caused by fasting.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6137948     DOI: 10.1093/ajcn/38.4.549

Source DB:  PubMed          Journal:  Am J Clin Nutr        ISSN: 0002-9165            Impact factor:   7.045


  12 in total

Review 1.  Promising new approaches to the management of obesity.

Authors:  I L Mertens; L F Van Gaal
Journal:  Drugs       Date:  2000-07       Impact factor: 9.546

Review 2.  The beta 3-adrenergic system and beta 3-adrenergic agonists.

Authors:  J R Arch
Journal:  Rev Endocr Metab Disord       Date:  2001-10       Impact factor: 6.514

Review 3.  Multiple actions of beta-adrenergic agonists on skeletal muscle and adipose tissue.

Authors:  Y T Yang; M A McElligott
Journal:  Biochem J       Date:  1989-07-01       Impact factor: 3.857

Review 4.  Options for the management of obesity.

Authors:  P L Beales; P G Kopelman
Journal:  Pharmacoeconomics       Date:  1994       Impact factor: 4.981

Review 5.  Beta 3-adrenoreceptor regulation of nitric oxide in the cardiovascular system.

Authors:  An L Moens; Ronghua Yang; Vabren L Watts; Lili A Barouch
Journal:  J Mol Cell Cardiol       Date:  2010-02-23       Impact factor: 5.000

Review 6.  Current concepts in the pharmacological management of obesity.

Authors:  P J Carek; L M Dickerson
Journal:  Drugs       Date:  1999-06       Impact factor: 9.546

Review 7.  The discovery of drugs for obesity, the metabolic effects of leptin and variable receptor pharmacology: perspectives from beta3-adrenoceptor agonists.

Authors:  Jonathan R S Arch
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-07-09       Impact factor: 3.000

8.  Weight loss in obese subjects on a restricted diet given BRL 26830A, a new atypical beta adrenoceptor agonist.

Authors:  A A Connacher; R T Jung; P E Mitchell
Journal:  Br Med J (Clin Res Ed)       Date:  1988-04-30

9.  Anti-hypertrophic and anti-oxidant effect of beta3-adrenergic stimulation in myocytes requires differential neuronal NOS phosphorylation.

Authors:  Vabren L Watts; Fernando M Sepulveda; Oscar H Cingolani; Alice S Ho; Xiaolin Niu; Rosa Kim; Karen L Miller; Koenraad Vandegaer; Djahida Bedja; Kathleen L Gabrielson; Gerald Rameau; Brian O'Rourke; David A Kass; Lili A Barouch
Journal:  J Mol Cell Cardiol       Date:  2013-05-02       Impact factor: 5.000

10.  Detection of thermogenesis in rodents in response to anti-obesity drugs and genetic modification.

Authors:  Jonathan R S Arch; Paul Trayhurn
Journal:  Front Physiol       Date:  2013-04-08       Impact factor: 4.566

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.